Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Florian Scotté, Luigi Celio, Yolanda Escobar, Alessandra Franceschetti, Karin Jordan, Danielle Bell, Matti Aapro, Richard Berman
Publikováno v:
Oncologist
Background Guideline-recommended antiemetic prophylaxis improves nausea and vomiting control in most patients undergoing chemotherapy. Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO) antiemeti
Autor:
Giada Rizzi, Lee S. Schwartzberg, Rebecca Clark-Snow, Ekaterine Arkania, Richard J. Gralla, Rudolph M. Navari, Matti Aapro, Daniel Voisin, Rita Wickham, Irena Radyukova, Kamal Patel, Eric Roeland
Publikováno v:
The Oncologist
Background NEPA, a combination antiemetic of a neurokinin‐1 (NK1) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5‐HT3RA, palonosetron] offers 5‐day CINV prevention with a single dose. Fosnetupitant solution co
Autor:
Toshinobu Hayashi, Mototsugu Shimokawa, Keisuke Aiba, Hitoshi Kawazoe, Kazuo Tamura, Toshiaki Saeki, Hirotoshi Iihara
Publikováno v:
The Oncologist
Background We previously reported the results of a prospective study of chemotherapy‐induced nausea and vomiting (CINV) in a cohort of patients who received carboplatin‐based chemotherapy and were selected from a nationwide registry of those sche
Autor:
Naoto Furukawa, Yuki Okada, Koji Oba, Kenji Okita, Yoshito Komatsu, Yoshimasa Kosaka, Luigi Celio, Satoshi Yuki, Matti Aapro
Publikováno v:
The Oncologist
Chemotherapy‐induced nausea and vomiting are common adverse effects associated with the use of cytotoxic chemotherapy drugs. This article evaluates differences in complete response rates and other antiemetic outcomes in dexamethasone‐spacing regi
Autor:
Hongyun Zhao, Likun Chen, Wenfeng Fang, Ting Zhou, Fangfang Gao, Yuanyuan Zhao, Gang Chen, Xue Hou, Shuxiang Ma, Yunpeng Yang, Xi Chen, Yaxiong Zhang, Yan Huang, Ningning Zhou, Li Zhang, Zhonghan Zhang, Cong Xue, Shaodong Hong, Yuxiang Ma, Jianhua Zhan, Fan Luo
Publikováno v:
The Oncologist. 23:603-616
Background The current antiemetic prophylaxis for patients treated with highly emetogenic chemotherapy (HEC) included the olanzapine-based triplet and neurokinin-1 receptor antagonists (NK-1RAs)-based triplet. However, which one shows better antiemet